Analysis of toxicokinetic data using NONMEM: impact of quantification limit and replacement strategies for censored data.
about
A Bayesian approach for PK/PD modeling with PD data below limit of quantification.The present and future of withdrawal period calculations for milk in the European Union: dealing with data below the limit of quantification.Handling data below the limit of quantification in mixed effect models.Evaluations of Bayesian and maximum likelihood methods in PK models with below-quantification-limit data.Estimating area under the curve and relative exposure in a pharmacokinetic study with data below quantification limit.Impact of low percentage of data below the quantification limit on parameter estimates of pharmacokinetic models.Extension of NPDE for evaluation of nonlinear mixed effect models in presence of data below the quantification limit with applications to HIV dynamic model.Clinical trial simulation to evaluate power to compare the antiviral effectiveness of two hepatitis C protease inhibitors using nonlinear mixed effect models: a viral kinetic approach.A multistate tuberculosis pharmacometric model: a framework for studying anti-tubercular drug effects in vitro.Prophylactic ranitidine treatment in critically ill children--a population pharmacokinetic study.Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid.Mrp4 confers resistance to topotecan and protects the brain from chemotherapy.Identification of cinnabarinic acid as a novel endogenous aryl hydrocarbon receptor ligand that drives IL-22 production.Extensions to the visual predictive check to facilitate model performance evaluation.Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance.
P2860
Q30573792-51224B44-DD91-4392-A7C3-1848945B82F4Q31118795-4AE3E570-DD80-4DCA-8DFC-22406E98A77BQ33447430-4F744401-2F37-40ED-9C4C-B8388490B2D2Q33521471-DAB9AC49-9917-4BF6-87FE-71B571B88E03Q33782019-A6C8B323-B168-4F20-A82A-4BE2B0BCF69DQ33917058-22171A9A-BDB7-42A5-AD07-41FC9D379FBBQ34376951-2533709A-8ED9-4501-96AA-055D11C5CECDQ34687255-195C1B26-5BF8-4ED1-AC48-2B33D1657FB3Q36684146-271FAD65-534E-4C86-87C5-CCF946BF478CQ36792973-637C78EC-0E87-46F8-A46E-C46CB4A08891Q37311185-82315A9B-4874-4BC4-A391-6414A3A94226Q37349714-628E9854-8AB9-46DE-BCA2-93473C143E43Q37549093-8C89EE93-A1D7-42FD-BBF8-F5E654D47F50Q42947696-66FB8685-4DBF-4605-8C12-F1DC3F13BAB7Q44108202-3334107C-43F7-40EA-97B6-2A92CAB026C5
P2860
Analysis of toxicokinetic data using NONMEM: impact of quantification limit and replacement strategies for censored data.
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Analysis of toxicokinetic data ...... strategies for censored data.
@ast
Analysis of toxicokinetic data ...... strategies for censored data.
@en
type
label
Analysis of toxicokinetic data ...... strategies for censored data.
@ast
Analysis of toxicokinetic data ...... strategies for censored data.
@en
prefLabel
Analysis of toxicokinetic data ...... strategies for censored data.
@ast
Analysis of toxicokinetic data ...... strategies for censored data.
@en
P2093
P356
P1476
Analysis of toxicokinetic data ...... strategies for censored data.
@en
P2093
Greenslade D
Woolfrey SG
P2888
P304
P356
10.1023/A:1012247131190
P577
2001-10-01T00:00:00Z
P6179
1045516753